PT - JOURNAL ARTICLE ED - , TI - â–¼Linezolid for Gram-positive infections AID - 10.1136/dtb.2001.39754 DP - 2001 Jul 01 TA - Drug and Therapeutics Bulletin PG - 54--56 VI - 39 IP - 7 4099 - http://dtb.bmj.com/content/39/7/54.short 4100 - http://dtb.bmj.com/content/39/7/54.full SO - Drug Ther Bull2001 Jul 01; 39 AB - Relevant BNF section: 5.1.7&#9660Linezolid* (Zyvox - Pharmacia) - the first oxazolidinone antibacterial - is marketed in the UK for treating hospital- and community-acquired pneumonia, skin and soft tissue infections. The manufacturer claims that switching from i.v. to oral administration of linezolid needs no dose adjustment and "will lead to early patient discharge and reduced hospital length of stay" for patients needing treatment for infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).1 Here, we assess the place of linezolid.